<DOC>
	<DOCNO>NCT00372788</DOCNO>
	<brief_summary>The purpose study assess effect safety AZD6244 ( ARRY-142886 ) versus pemetrexed second third line treatment advance Non-Small Cell Lung Cancer . Following baseline assessment , minimum 64 patient approximately 5-6 center US treat either AZD6244 pemetrexed . Treatment continue long patient receive clinical benefit .</brief_summary>
	<brief_title>AZD6244 Versus Pemetrexed ( AlimtaÂ® ) Patients With Non-small Cell Lung Cancer , Who Have Failed One Two Prior Chemotherapy Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosed nonsmall cell lung cancer Previously receive one two chemotherapeutic treatment Previous therapy MEK inhibitor pemetrexed Any recent surgery , unhealed surgical incision severe condition uncontrolled cardiac disease chronic gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
	<keyword>AZD6244</keyword>
</DOC>